Last reviewed · How we verify
Sandostatin (OCTREOTIDE)
Sandostatin works by mimicking the natural hormone somatostatin to inhibit the release of various hormones and growth factors.
Sandostatin (Octreotide) is a somatostatin analog developed by Novartis, targeting the somatostatin receptor type 2. It is a small molecule drug class, approved by the FDA in 1988 for various indications including acromegaly, carcinoid syndrome, and diarrhea from pancreatic VIPoma. As an off-patent medication, it is available from multiple generic manufacturers. Key safety considerations include its short half-life of 1.7 hours and low bioavailability of 2%. Sandostatin is commercially available, with no active Orange Book patents.
At a glance
| Generic name | OCTREOTIDE |
|---|---|
| Sponsor | Novartis |
| Drug class | Somatostatin Analog |
| Target | Somatostatin receptor type 2 |
| Modality | Recombinant protein |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1988 |
| Annual revenue | 305 |
Mechanism of action
Octreotide exerts pharmacologic actions similar to the natural hormone somatostatin, but is more potent inhibitor of GH, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses luteinizing hormone (LH) response to gonadotropin-releasing hormone (GnRH), decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide.
Approved indications
- Acromegaly
- Carcinoid syndrome
- Congenital hyperinsulinism
- Diarrhea from Pancreatic VIPoma
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Loose stools
- Sinus bradycardia
- Conduction abnormalities
- Arrhythmias
- Hypoglycemia
- Hyperglycemia
- Biochemical hypothyroidism
- Goiter
- Pain on injection
Key clinical trials
- Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly (PHASE3)
- Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome (PHASE2)
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
- Hoffa's Fat Pad Impingement (HFPI) (PHASE4)
- Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome (PHASE2)
- Octreotide Microspheres for Preventing Pancreatic Fistula (PHASE3)
- Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome (NA)
- Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sandostatin CI brief — competitive landscape report
- Sandostatin updates RSS · CI watch RSS
- Novartis portfolio CI